This pioneering research meticulously sifted through safety reports submitted between April 1, 2022, and December 31, 2024, encapsulating a sizable cohort of 7,654 patients primarily identified as having been treated with Pluvicto®. The temporal distribution of these reports conspicuously indicated a monthly uptrend in AE reporting frequency, signaling an escalating clinical adoption that is paralleled by a growing pharmacovigilance dataset. Demographically, the analysis highlighted a noteworthy subset of patients weighing 90 kilograms or more, corresponding to nearly one-quarter of the cases, underscoring the necessity of weight-based considerations in therapeutic management.

To unravel the complex interface between Pluvicto® administration and patient safety, researchers classified the reported adverse events according to the Medical Dictionary for Regulatory Activities (MedDRA®), enabling a standardized taxonomy based on System Organ Classes (SOCs) and preferred terms (PTs). Out of an initial pool of 649 distinct PTs, 33 statistically significant signals were robustly identified through the convergence of four independent pharmacovigilance algorithms: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). These signals spanned across 10 SOC categories, with 15 AE signals demonstrating a compelling correlation to the pharmacologic action of Lutetium-177-PSMA-617.

A key insight from the temporal analysis of adverse events was the observation that most AEs manifested within the first three months following treatment initiation, illuminating a critical window for clinical vigilance. Among different organ systems, nervous system disorders were distinctive for their rapid onset, often surfacing within the first 10 days post-administration. This early-onset pattern accentuates the need for heightened neurologic monitoring immediately after treatment, as early detection and intervention could mitigate long-term complications.

Beyond the well-characterized hematologic toxicities traditionally associated with radioligand therapies, the study uncovered consistent high-signal AEs including xerostomia (dry mouth), abnormalities in laboratory tests, and general physical health deterioration. These findings resonate with prior clinical observations but now gain quantitative backing from a comprehensive real-world data environment, reinforcing the multifaceted impact of Pluvicto® on patient health beyond tumor control.

Particular attention is warranted for patients exceeding the 90 kg weight threshold, where the incidence and significance of AEs appeared amplified. This weight-related vulnerability suggests that individualized dosing strategies or enhanced supportive measures may be required to optimize safety profiles for heavier patients. With the increasing global rollout of Pluvicto®, integrating such nuanced clinical insights is paramount to tailoring therapy and mitigating risks.

The rigorous application of disproportionality analysis techniques in this study exemplifies how modern pharmacovigilance leverages large-scale spontaneous reporting systems to generate clinically actionable intelligence. By cross-validating AE signals through multiple statistical algorithms, the research delivers a high degree of confidence in the detected associations, thereby paving the way for improved safety guidelines and patient monitoring protocols.

Moreover, the temporal profiling adds an invaluable dimension to understanding the kinetics of adverse reactions. The identification of distinct early-onset versus delayed-onset toxicities provides clinicians with a temporal roadmap for surveillance and intervention, facilitating proactive patient management rather than reactive treatment of complications.

The study also highlights the indispensable role of laboratory assessments — intensified and diversified screening could preemptively flag subclinical toxicities, allowing timely adjustment of therapy or supportive care. This aligns with modern precision medicine paradigms, where dynamic monitoring underpins safe and effective oncologic treatments.

In conclusion, this robust disproportionality analysis of the FDA’s FAERS database reaffirms the known safety signals linked with Lutetium-177-PSMA-617 while unveiling novel considerations for clinical practice. It advocates for heightened awareness of early neurologic symptoms, comprehensive laboratory screening, and the incorporation of patient-specific characteristics such as body weight into therapeutic decision-making. As Pluvicto® continues to redefine treatment landscapes for advanced prostate cancer, such real-world evidence studies are critical to safeguarding patient outcomes and optimizing the clinical benefit-risk balance.

This investigation offers a template for future pharmacovigilance in oncology, demonstrating how large data repositories and sophisticated analytic frameworks collaboratively enhance drug safety knowledge. Ultimately, these insights bolster clinicians’ capacity to harness the therapeutic potential of novel agents like Pluvicto®, while vigilantly managing their adverse effect profiles in diverse patient populations.

Subject of Research: Adverse events related to Lutetium-177-PSMA-617 (Pluvicto®) in the treatment of metastatic castration-resistant prostate cancer, using data from the FDA’s Adverse Event Reporting System.

Article Title: Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto®) in advanced prostate cancer: a disproportionality analysis based on the FDA’s adverse event reporting system (FAERS).

Article References: Jin, Y., Zhang, Y., Wang, M. et al. Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto®) in advanced prostate cancer: a disproportionality analysis based on the FDA’s adverse event reporting system (FAERS). BMC Cancer 25, 1470 (2025). https://doi.org/10.1186/s12885-025-14846-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14846-x

The study systematically extracted data spanning nearly a decade, from the first quarter of 2014 through the last quarter of 2023, identifying a total of 1,112 cases involving 1,134 adverse event reports specifically linked to ICI-associated noninfectious myocarditis and pericarditis (NM/P). This scope of data—carefully curated from a vast pharmacovigilance repository—provides an unparalleled real-world insight into the epidemiology and risk factors underpinning these life-threatening complications.

A key finding of the research lies in the demographic and clinical profiles of affected patients. The median age was 67 years, indicating a preponderance of older adults in the reported cases, consistent with the typical cancer patient population receiving ICIs. Men were disproportionately represented, suggesting potential sex-related susceptibility that warrants further immunological and pharmacogenomic investigation. The median body weight was recorded at 65 kilograms, although an intriguing trend emerged: patients weighing 75 kilograms or more appeared to face heightened risk, indicating that body mass might modulate drug pharmacodynamics with implications for dosage and monitoring.

Temporal analysis revealed a median onset time of just 28 days from initiation of ICI therapy to the manifestation of myocarditis or pericarditis symptoms. This rapid timeline underscores the necessity for vigilant cardiac monitoring early in treatment courses, as delayed recognition can culminate in severe morbidity or mortality. Indeed, the mortality risk associated with these cardiac irAEs was markedly elevated, particularly in patients treated with nivolumab and pembrolizumab, two of the most widely prescribed programmed death-1 (PD-1) inhibitors.

From a pharmacovigilance standpoint, the study applied two sophisticated disproportionality analysis techniques: the Bayesian Confidence Propagation Neural Network (BCPNN) and the Reporting Odds Ratio (ROR). These statistical methods serve to detect and quantify signals of potential drug-associated adverse effects by contrasting observed reports against expected baselines. The results pointed to a hierarchy of risk, where pembrolizumab exhibited the strongest signal (ROR: 12.32, IC 025: 3.45), followed closely by nivolumab (ROR: 11.23, IC 025: 3.30), indicating more than a tenfold increase in reporting frequency for NM/P compared to other agents. Similarly, atezolizumab, ipilimumab, and durvalumab displayed significant but slightly lower signals, suggesting that while the risk is inherent to the ICI class, it may vary based on specific molecular targets or drug structures.

Importantly, the combination of nivolumab and ipilimumab—a regimen increasingly favored for its synergistic antitumor efficacy—emerged as a notable risk factor. The amplified immune activation achieved by dual checkpoint blockade appears to come at the cost of increased cardiac irAEs, demanding a fine balance between therapeutic benefit and safety vigilance. This insight compels oncologists and cardiologists to collaborate closely in managing patients slated for combination immunotherapy.

The underlying mechanisms driving ICI-induced myocarditis and pericarditis remain an active area of scientific inquiry. It is hypothesized that immune checkpoint blockade disrupts self-tolerance by unleashing autoreactive T-cells against cardiac tissues, thereby initiating inflammatory cascades and tissue injury. This autoimmune-like pathology differs fundamentally from infectious or ischemic causes and necessitates targeted immunosuppressive interventions to reverse cardiac inflammation and preserve function.

Emerging evidence also suggests that certain patient-specific factors, such as baseline immune status, genetic predispositions, and concurrent medications, could modulate the risk profile for cardiac toxicities. The present pharmacovigilance analysis provides a foundational dataset that could inform future prospective studies aimed at delineating predictive biomarkers and personalized risk stratification tools.

The geographic distribution of reports highlights a predominance from the United States and Japan, reflecting both the widespread clinical adoption of ICIs in these regions and possibly differences in pharmacovigilance infrastructure and reporting cultures. Engaging diverse populations globally in active surveillance will be critical to ascertain the universality of these findings and to address potential disparities.

As the oncology community embraces ICIs as mainstays in treating a range of solid tumors and hematologic malignancies, this study serves as a clarion call to integrate cardiac safety monitoring protocols into routine clinical workflows. Early detection of myocarditis and pericarditis—through biomarkers such as troponins, echocardiography, and cardiac MRI—paired with prompt intervention can mitigate severe outcomes.

Ultimately, the balance between therapeutic efficacy and toxicity management defines the future of cancer immunotherapy. The insights gleaned from this large-scale FAERS analysis emphasize the need for heightened awareness, proactive monitoring, and multidisciplinary care to safeguard patients from potentially fatal cardiac adverse events.

The implications of this research resonate beyond clinical oncology. They prompt pharmaceutical developers to innovate next-generation ICIs with reduced off-target immune activation and encourage regulatory agencies to refine post-marketing surveillance frameworks that incorporate sophisticated analytics like BCPNN and ROR. Moreover, the establishment of international registries dedicated to immune-related cardiotoxicity could expedite knowledge dissemination and best practice formulation.

In conclusion, immune checkpoint inhibitor-associated myocarditis and pericarditis represent formidable challenges in cancer therapeutics. This comprehensive pharmacovigilance study illuminates significant risk signals, identifies susceptible patient subgroups, and underscores the urgency of integrating cardiology expertise into oncologic care paradigms. As immunotherapy continues to evolve, such data-driven insights are indispensable to maximizing patient benefit while minimizing harm, ultimately advancing the frontier of personalized cancer treatment.

Article Title: Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database

Article References:
Yao, G., Zhang, Y., Zhang, H. et al. Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database. BMC Cancer 25, 1294 (2025). https://doi.org/10.1186/s12885-025-14668-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14668-x

A groundbreaking study recently published in eClinicalMedicine presents the most comprehensive investigation to date into the phenomenon of SPMs following CAR-T therapy. A multidisciplinary team of researchers from Southern Medical University in China undertook an observational study utilizing global pharmacovigilance databases, including the FDA Adverse Event Reporting System (FAERS) and VigiBase, to analyze secondary cancer risks post-CAR-T treatment on an unprecedented scale. Their dataset encompassed 607 reported cases of secondary malignancies occurring from 2017 through 2023, providing crucial insights into frequency, timing, and cancer subtypes linked with post-treatment risks.

The study reveals a notable, statistically significant increase in the incidence of SPMs among CAR-T recipients. Analysis showed an 8.9-fold elevated risk of developing T-cell lymphoma and a 3.5-fold higher risk of myelodysplastic syndromes compared to patients who did not undergo CAR-T therapy. These malignancies are particularly concerning given their aggressive nature and treatment challenges. The precise mechanisms underlying the increased susceptibility remain to be fully elucidated but may involve CAR-T cell-induced changes in immune homeostasis, off-target effects, or prior exposure to cytotoxic agents that sensitize hematopoietic progenitors to malignant transformation.

One of the most alarming findings pertains to the temporal dynamics of secondary cancers post-CAR-T therapy. Whereas typical secondary cancers in other cancer treatment contexts often emerge after extended latency periods, this research highlights an accelerated timeline in CAR-T recipients. The median onset for SPMs in the CAR-T cohort was 282 days post-therapy, markedly earlier compared to 526 days in matched controls. This suggests that the immunologic and microenvironmental alterations induced by CAR-T therapy may accelerate carcinogenesis or unmask latent malignant clones at an earlier stage than previously recognized.

An age-specific risk pattern was also identified. Pediatric and young adult patients under the age of 40 experienced secondary malignancies within an extraordinarily compressed median timeframe of just 35 days following CAR-T administration. This rapid emergence of secondary cancers in younger populations raises critical questions about the interplay between developmental immune system factors, CAR-T cell dynamics, and genetic susceptibilities. It underscores the urgent need for age-tailored surveillance strategies and long-term follow-up protocols.

The study’s authors emphasize the significance of their findings in the broader context of CAR-T therapy safety monitoring. Dr. Peng Luo, the corresponding author, elaborates that comprehensive pharmacovigilance is imperative to optimize risk-benefit profiles of CAR-T treatments. “While CAR-T therapy has revolutionized outcomes for hematologic malignancies, understanding the nuances of secondary malignancy risks is essential for informed clinical decision-making and patient counseling,” Luo asserts. The use of large-scale real-world data sources such as FAERS and VigiBase enables an unprecedented breadth of population-level insights that complement smaller clinical cohort studies.

Another important clinical implication concerns the necessity for refined post-CAR-T patient management. The authors advocate for the integration of routine screening programs customized by patient age and risk profile to detect SPMs early. They endorse the recent United States Food and Drug Administration (FDA) directive mandating lifelong monitoring of CAR-T recipients. Implementing these guidelines will require multidisciplinary coordination across hematology, oncology, pathology, and immunology specialties, alongside enhanced patient education on symptom vigilance.

Despite the compelling evidence, these findings also raise several mechanistic research questions that warrant further investigation. It remains unclear how the genetic modifications intrinsic to CAR-T cells may influence host genomic stability or induce pro-oncogenic inflammation within the bone marrow niche. Additionally, interactions between CAR-T therapy and patients’ prior treatment histories require detailed analysis. The complex immunologic milieu shaped by CAR-T, including cytokine release syndrome and prolonged cytopenias, may create a permissive environment conducive to malignant evolution.

The research team underscored a transparent conflict-of-interest statement, affirming no financial or personal affiliations that could bias results. This objective stance enhances confidence in the integrity of their analyses and conclusions. The funding sources included prominent grants from the Natural Science Foundation of Guangdong Province and several national Chinese scientific foundations, reflecting robust institutional support for advancing CAR-T safety research.

While the promise of CAR-T therapy remains unquestionable, this study serves as a timely reminder of the vigilance necessary in adopting novel biotechnologies at scale. Awareness of secondary primary malignancies as a tangible risk factors will inform clinicians, researchers, and patients alike. Through ongoing global surveillance, molecular investigations, and iterative improvements in CAR-T engineering, it is hoped that secondary cancer risks can be mitigated without compromising therapeutic efficacy.

In summary, the comprehensive examination of two major pharmacovigilance databases illuminates a critical safety dimension of CAR-T therapy that has previously been underappreciated. The significantly heightened risks of T-cell lymphoma and myelodysplastic syndromes, the accelerated onset of SPMs post-treatment, and the vulnerability of younger patients represent pivotal concerns warranting clinical and scientific attention. This work calls for systematic inclusion of SPM risk assessments in future CAR-T clinical trial designs and post-market surveillance programs, establishing a paradigm of proactive safety vigilance aligned with the ongoing revolution in cellular immunotherapy.

As CAR-T approaches continue to evolve, integrating next-generation engineering techniques and combinatorial immunomodulatory regimens, the insights gained from this study will be instrumental in shaping safer treatment paradigms. Moving forward, multidisciplinary collaboration encompassing clinicians, biologists, and regulatory agencies will be essential in balancing transformative therapeutic benefits with long-term health risks inherent in manipulating human immunity at the cellular level.

Subject of Research: People

Article Title: Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase

Web References: http://dx.doi.org/10.1016/j.eclinm.2024.102684

Image Credits: Junyi Shen et al.

Keywords: Cancer

Lung cancer remains a formidable adversary in global oncology, persisting as one of the leading causes of cancer-related mortality. While platinum-based chemotherapies paired with pemetrexed have long served as cornerstones of treatment, the advent of pembrolizumab—a programmed death-1 (PD-1) inhibitor—has revolutionized therapeutic strategies. Pembrolizumab’s mechanism, by reactivating the immune response against tumor cells, significantly augments clinical efficacy, yet simultaneously poses challenges in managing immune-related adverse events.

Leveraging the vast repository of post-marketing surveillance data within FAERS, researchers analyzed adverse event reporting trends spanning from mid-2017 to late 2024. This timeframe captures the progressive adoption of pembrolizumab in clinical practice and allows for a robust comparative safety assessment between chemotherapy alone and its combination with immunotherapy. The utilization of sophisticated statistical measures including the Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) ensured a nuanced detection of disproportionality signals amid the vast dataset.

The study encompassed a considerable pool of adverse event reports, with 2,871 cases linked to chemotherapy alone and 5,443 reports associated with the addition of pembrolizumab. This disparity underscores the growing clinical reliance on combination regimens but also highlights the imperative need to dissect the safety landscape meticulously. Intriguingly, combination therapy revealed a conspicuous elevation in the incidence of renal and urinary disorders, hepatobiliary complications, as well as respiratory conditions such as interstitial lung disease and pneumonitis.

Of particular concern is the identification of interstitial lung disease (ILD) and pneumonitis as emergent adverse events that surfaced with greater frequency under combination treatment. These pulmonary toxicities not only bear significant morbidity but also complicate ongoing management, necessitating vigilant monitoring protocols. The researchers’ findings advocate for heightened clinical awareness, especially in the critical initial three months post-treatment commencement—a window wherein the onset of adverse events appears most pronounced.

Delving deeper, the study dissected subgroup variations, unearthing that patient-specific factors such as gender and age materially influence susceptibility to adverse reactions. This insight dovetails with the broader imperative for personalized medicine; tailoring surveillance and therapeutic adjustments to patient demographics could mitigate risks and enhance tolerability. The differential impact observed across these subgroups also prompts further investigation into underlying biological or pharmacokinetic mechanisms.

An additional facet of clinical importance is the altered timeline of adverse event manifestation observed with combination therapy. Unlike chemotherapy alone, where adverse events tend to present relatively rapidly, the inclusion of pembrolizumab was associated with a prolonged time to onset. This delayed toxicity potential demands extended follow-up and may have profound implications for long-term patient management and quality of life.

The methodology underpinning this pharmacovigilance study is noteworthy for its integration of multiple disproportionality algorithms. These analytical tools—spanning frequentist approaches like ROR and PRR to Bayesian frameworks like BCPNN and MGPS—fortify the rigor of signal detection. Such multi-dimensional analysis mitigates the risk of false positives and enhances confidence in identifying true safety concerns within heterogeneous real-world data.

While randomized clinical trials (RCTs) remain the gold standard for efficacy and preliminary safety evaluation, post-marketing surveillance via the FAERS database offers invaluable real-world insights that RCTs may miss. Variations in patient populations, co-morbidities, and treatment adherence encountered in routine practice accentuate the relevance of these findings, reinforcing the nuanced toxicity spectrum that emerges beyond controlled trial settings.

These revelations bear significant clinical repercussions. Oncologists must navigate the therapeutic promise of pembrolizumab-enhanced regimens against a backdrop of heightened adverse event risk. Early detection strategies, thorough patient education, and tailored monitoring—especially among vulnerable subgroups—are essential to optimize outcomes while minimizing harm. Furthermore, these data could guide modification of treatment protocols to balance efficacy with safety.

Future research trajectories might encompass mechanistic explorations to elucidate why combination therapy predisposes patients to renal, hepatic, and pulmonary toxicities. Additionally, integrating biomarker studies could enable preemptive identification of patients at elevated risk, potentially refining candidate selection for combination protocols. Such precision oncology approaches would harmonize therapeutic aggressiveness with safety considerations.

This study also underscores the evolving role of pharmacovigilance databases as critical instruments in contemporary oncology. Harnessing big data analytics enables clinicians and regulators to detect emerging drug safety signals promptly, fostering adaptive strategies in cancer care. The convergence of immunotherapy with chemotherapy, while transformative, therefore necessitates continuous vigilance and dynamic evidence synthesis.

In summary, the confluence of pemetrexed, platinum, and pembrolizumab in lung cancer treatment exemplifies both therapeutic innovation and complexity. This comprehensive FAERS analysis delineates a heightened yet manageable risk landscape, reinforcing the import of personalized treatment paradigms and vigilant adverse event monitoring. As immune-oncology continues to advance, such insights will be indispensable in refining the delicate equilibrium between treatment benefits and potential harms.

The journey toward conquering lung cancer is marked by incremental yet significant strides. Integrating real-world evidence into clinical decision-making not only deepens understanding of treatment safety but also empowers clinicians to optimize patient-centric care. With enhanced awareness of these adverse event profiles, the oncology community can better harness the full potential of immuno-chemotherapy combinations, navigating challenges toward improved survival and quality of life for patients worldwide.

—

Subject of Research: The safety profile and adverse event risks associated with pemetrexed and platinum chemotherapy with or without pembrolizumab in lung cancer patients, analyzed through the FAERS pharmacovigilance database.

Article Title: The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database

Article References:

Li, S., Huang, Z., Zhong, X. et al. The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database.
BMC Cancer 25, 767 (2025). https://doi.org/10.1186/s12885-025-14171-3

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14171-3